|Datasheet||Specific References||Reviews||Related Products||Protocols|
|ORF Clone of chymotrypsin-like DNA.|
|CTRL1, MGC70821, CTRL|
|Identical with the Gene Bank Ref. ID sequence.|
|Whatman FTA elute card (Cat: WB120410) contains 5-10 μg of plasmid.|
|The Whatman FTA elute card can be stored at room temperature for three months under dry condition.|
The pGEM-T is 3kb in length, and contains the amplicin resistance gene, conferring selection of the plasmid in E. coli, and the ori site which is the bacterial origin of replication. The plasmid has multiple cloning sites as shown below. The coding sequence was inserted by TA cloning. Many E. coli strains are suitable for the propagation of this vector including JM109, DH5α and TOP10.
The coding sequence can be easily obtained by digesting the vector with proper restriction enzyme(s). The coding sequence can also be amplified by PCR with M13 primers, or primer pair SP6 and T7.
|Human CTRL Gene cDNA Clone (full-length ORF Clone), expression ready, FLAG-tagged||HG13748-G-F|
|Human CTRL Gene cDNA Clone (full-length ORF Clone), expression ready, His-tagged||HG13748-G-H|
|Human CTRL Gene cDNA Clone (full-length ORF Clone), expression ready, Myc-tagged||HG13748-G-M|
|Human CTRL Gene cDNA Clone (full-length ORF Clone), expression ready, untagged||HG13748-G-N|
|Human CTRL Gene cDNA Clone (full-length ORF Clone), expression ready, HA-tagged||HG13748-G-Y|
|Product name||Product name|
CTRL-1, also known as chymotrypsin-like protease, belongs to the peptidase S1 family. CTRL-1 contains 1 peptidase S1 domain. Its expression is increased in preeclampsia (PE). Placental-derived chymotrypsin-like protease is responsible for inducing endothelial inflammatory phenotypic changes possibly by upregulation of cell adhesion molecule expressions, activation of cellular protease, and induction of extracellular regulated kinase phosphorylation. Activated microglia have been observed in various neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis, and multiple sclerosis. Five structurally distinct inhibitors that are known to inhibit chymotrypsin-like proteases were partially protective. They might represent a novel class of drugs with benefit in diseases where overactivity of microglia contributes to the pathogenesis.